APLS Jan 2026 90.000 call
| Previous close | 8.95 |
| Open | 8.75 |
| Bid | 4.30 |
| Ask | 5.90 |
| Strike | 90.00 |
| Expiry date | 2026-01-16 |
| Day's range | 8.10 - 9.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 84 |
ZacksAnalysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireApellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The 11 oral
ZacksWill Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
